Enterocolitis - Pipeline Review, H2 2015

Publisher Name :
Date: 09-Dec-2015
No. of pages: 43
Inquire Before Buying

Global Markets Direct's, ‘Enterocolitis - Pipeline Review, H2 2015', provides an overview of the Enterocolitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Enterocolitis

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Enterocolitis and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Enterocolitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Enterocolitis pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Enterocolitis

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Enterocolitis - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterocolitis Overview 6
Therapeutics Development 7
Pipeline Products for Enterocolitis - Overview 7
Pipeline Products for Enterocolitis - Comparative Analysis 8
Enterocolitis - Therapeutics under Development by Companies 9
Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10
Enterocolitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Enterocolitis - Products under Development by Companies 13
Enterocolitis - Products under Investigation by Universities/Institutes 14
Enterocolitis - Companies Involved in Therapeutics Development 15
Angothera GmbH 15
AvidBiotics Corp. 16
Infant Bacterial Therapeutics AB 17
Sigma-Tau Pharmaceuticals, Inc 18
Enterocolitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
Antibodies for Enterocolitis - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AvR2-V10 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
C-34 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IBP-9414 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NRG-4 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
STP-206 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Enterocolitis - Recent Pipeline Updates 37
Enterocolitis - Dormant Projects 38
Enterocolitis - Product Development Milestones 39
Featured News & Press Releases 39
Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 39
Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 39
Apr 01, 2015: Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis 39
Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 40
Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 40
Feb 04, 2014: Sigma-Tau Pharmaceuticals Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants 41
Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Enterocolitis, H2 2015 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Enterocolitis - Pipeline by Angothera GmbH, H2 2015 15
Enterocolitis - Pipeline by AvidBiotics Corp., H2 2015 16
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2015 17
Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Enterocolitis Therapeutics - Recent Pipeline Updates, H2 2015 37
Enterocolitis - Dormant Projects, H2 2015 38

List of Figures

Number of Products under Development for Enterocolitis, H2 2015 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Targets, H2 2015 20
Number of Products by Stage and Targets, H2 2015 20
Number of Products by Mechanism of Actions, H2 2015 22
Number of Products by Stage and Mechanism of Actions, H2 2015 22
Number of Products by Stage and Routes of Administration, H2 2015 24
Number of Products by Molecule Types, H2 2015 25
Number of Products by Stage and Molecule Types, H2 2015 25
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Global Hypercalcemia Treatment Market 2017-2021
    Published: 19-Apr-2017        Price: US 3500 Onwards        Pages: 70
    ABSTRACT About Hypercalcemia Treatment Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by ma......
  • Friedreich Ataxia - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 85
    Friedreich Ataxia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape. Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed dow......
  • Liver Fibrosis - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 200
    Liver Fibrosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the l......
  • Fragile X Syndrome - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 108
    Fragile X Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, re......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
    Published: 05-Apr-2017        Price: US 3500 Onwards        Pages: 70
    HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to variou......
  • Sarcopenia - Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Epidemiology Forecast To 2023" Report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after......
  • Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017
    Published: 01-Apr-2017        Price: US 2450 Onwards        Pages: 207
    DelveInsight's report, "Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017", emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development. The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on t......
  • Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
    Published: 01-Apr-2017        Price: US 4950 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM" Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most peopl......
  • Acromegaly and Gigantism- Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's"Acromegaly and Gigantism- Epidemiology Forecast to 2023" Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk fact......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs